Abstract
Alzheimer’s disease (AD) is a looming public health crisis that currently lacks an effective treatment. Noninvasive Brain Stimulation (NBS), particularly transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), offers a promising alternative approach to pharmacological interventions for an increasing number of neurological and psychiatric conditions. The aim of this review is summarize data from therapeutic trials of NBS in AD and other dementing illnesses.
Despite the potential of NBS, there is limited theoretical framework and a lack of guidelines for its applications to AD. Several published clinical trials failed to report key parameters of the interventions thus limiting the utility of the study to assess efficacy and safety. Our review concludes with some suggestions for future studies aimed to advance research into NBS as a potential treatment for the symptoms and disabilities caused by AD and to enable comparison of results across trials. Ultimately, appropriately powered, and controlled, multi-site randomized clinical trials will be needed to evaluate the therapeutic potential of NBS in AD.Keywords: Alzheimer's disease, transcranial magnetic stimulation, TMS, tDCS, dementia, noninvasive brain stimulation, NBS.
Current Alzheimer Research
Title:Therapeutic Noninvasive Brain Stimulation in Alzheimer’s Disease
Volume: 14 Issue: 4
Author(s): Irene Gonsalvez, Roey Baror, Peter Fried, Emiliano Santarnecchi and Alvaro Pascual-Leone
Affiliation:
Keywords: Alzheimer's disease, transcranial magnetic stimulation, TMS, tDCS, dementia, noninvasive brain stimulation, NBS.
Abstract: Alzheimer’s disease (AD) is a looming public health crisis that currently lacks an effective treatment. Noninvasive Brain Stimulation (NBS), particularly transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), offers a promising alternative approach to pharmacological interventions for an increasing number of neurological and psychiatric conditions. The aim of this review is summarize data from therapeutic trials of NBS in AD and other dementing illnesses.
Despite the potential of NBS, there is limited theoretical framework and a lack of guidelines for its applications to AD. Several published clinical trials failed to report key parameters of the interventions thus limiting the utility of the study to assess efficacy and safety. Our review concludes with some suggestions for future studies aimed to advance research into NBS as a potential treatment for the symptoms and disabilities caused by AD and to enable comparison of results across trials. Ultimately, appropriately powered, and controlled, multi-site randomized clinical trials will be needed to evaluate the therapeutic potential of NBS in AD.Export Options
About this article
Cite this article as:
Gonsalvez Irene, Baror Roey, Fried Peter, Santarnecchi Emiliano and Pascual-Leone Alvaro, Therapeutic Noninvasive Brain Stimulation in Alzheimer’s Disease, Current Alzheimer Research 2017; 14 (4) . https://dx.doi.org/10.2174/1567205013666160930113907
DOI https://dx.doi.org/10.2174/1567205013666160930113907 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroprotective Effects of Lutein in the Retina
Current Pharmaceutical Design The Recent Development of α<sub>7</sub> Nicotinic Acetylcholine Receptor (nAChR) Ligands as Therapeutic Candidates for the Treatment of Central Nervous System (CNS) Diseases
Current Pharmaceutical Design Free Fatty Acids: Circulating Contributors of Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Anti-Vascular Endothelial Growth Factor Drug Treatment of Diabetic Macular Edema: The Evolution Continues
Current Diabetes Reviews Subclinical Thyroid Dysfunction and the Risk of Cardiovascular Disease
Current Pharmaceutical Design Recent Advances in Nanotechnology-Based Drug Delivery Approaches for Alzheimer disease
Current Drug Targets Bright Light Delights: Effects of Daily Light Exposure on Emotions, Restactivity Cycles, Sleep and Melatonin Secretion in Severely Demented Patients
Current Alzheimer Research BK Channel Modulators: A Comprehensive Overview
Current Medicinal Chemistry Therapeutic Opportunities for Trophic Factors in Brain Inflammation
Current Pharmaceutical Analysis Meet Our Editorial Board Member:
Current Neuropharmacology Quality of Education and Memory Test Performance in Older Men: The New York University Paragraph Recall Test Normative Data
Current Alzheimer Research Relationship of Neurofilament Light (NfL) and Cognitive Performance in a Sample of Mexican Americans with Normal Cognition, Mild Cognitive Impairment and Dementia
Current Alzheimer Research Flavonoids in Human Health: From Structure to Biological Activity
Current Nutrition & Food Science Beta-blockers in the Perioperative Period: Are there Indications other than Prevention of Cardiac Ischemia?
Current Drug Targets Benefit of 13-desmethyl Spirolide C Treatment in Triple Transgenic Mouse Model of Alzheimer Disease: Beta-Amyloid and Neuronal Markers Improvement
Current Alzheimer Research Molecular Mechanism of Autophagy: Its Role in the Therapy of Alzheimer’s Disease
Current Neuropharmacology Platelets and Vascular Risk: An Option for Treatment
Current Pharmaceutical Design Uridine Function in the Central Nervous System
Current Topics in Medicinal Chemistry Systemic Oxidative Stress in Older Patients with Mild Cognitive Impairment or Late Onset Alzheimer's Disease
Current Alzheimer Research Classical Neurotransmitters and Neuropeptides Involved in Parkinson's Disease: Focus on Anti-Parkinsonian Drugs
Current Drug Therapy